Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Investigating the role of Bcl-2 family proteins in T cell activation and anti-leukemic activity against acute myeloid leukemia
FY 2024-25
Summary
Supervisor: Dr. Aaron Schimmer, University of Toronto.
Acute myeloid leukemia (AML) is the most common form of adult leukemia. AML is associated with a poor long-term survival rate, with less than 5% of older patients survive 5 years or longer after diagnosis. Recent studies showed that 70% of newly diagnosed patients who are unfit for standard chemotherapy respond to Venetoclax, an FDA-approved drug. However, only 25-40% of patients with disease that re-occurs respond to Venetoclax. Adoptive cell therapy, which uses immune cells such as T cells derived from patients or healthy donors to attack cancer, has recently achieved success in several types of blood cancers and is being evaluated in clinical trials for AML. Recently, our lab showed that Venetoclax can enhance the ability of T cells to target AML cells. Venetoclax works by inhibiting the activity of B-cell lymphoma-2 (Bcl-2) protein, a member of Bcl-2 family proteins. However, the role of Bcl-2 family proteins in T cells is not well understood. The goal of this project is to determine the role of Bcl-2 family proteins in T cell activity to understand the effects of Venetoclax on T cells and develop novel strategies for treating AML. We will examine the levels of Bcl-2 family proteins in T cells of AML patients and the effect of inhibiting Bcl-2 family proteins on the ability of T cells to target AML. In culture and animal models, we will evaluate the efficacy of Bcl-2 family inhibitor drugs for treating AML alone or in combination with other cancer therapy. We anticipate that Bcl-2 family protein levels are increased in T cells of AML patients and associated with T cell dysfunction. We also expect that Bcl-2 family inhibitors will enhance the ability of T cells to target AML and work synergistically with other cancer therapy. Successful development of Bcl-2 family inhibitors as novel therapy for AML will provide a new approach for treating relapsed AML and increase the overall survival rate of AML patients.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
517111
Name
Fang Karen Kai-Lin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Investigating the role of Bcl-2 family proteins in T cell activation and anti-leukemic activity against acute myeloid leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Adoptive Cell Therapy; B-Cell Lymphoma-2; T Cell; Venetoclax
Abstract
Supervisor: Dr. Aaron Schimmer, University of Toronto.
Acute myeloid leukemia (AML) is the most common form of adult leukemia. AML is associated with a poor long-term survival rate, with less than 5% of older patients survive 5 years or longer after diagnosis. Recent studies showed that 70% of newly diagnosed patients who are unfit for standard chemotherapy respond to Venetoclax, an FDA-approved drug. However, only 25-40% of patients with disease that re-occurs respond to Venetoclax. Adoptive cell therapy, which uses immune cells such as T cells derived from patients or healthy donors to attack cancer, has recently achieved success in several types of blood cancers and is being evaluated in clinical trials for AML. Recently, our lab showed that Venetoclax can enhance the ability of T cells to target AML cells. Venetoclax works by inhibiting the activity of B-cell lymphoma-2 (Bcl-2) protein, a member of Bcl-2 family proteins. However, the role of Bcl-2 family proteins in T cells is not well understood. The goal of this project is to determine the role of Bcl-2 family proteins in T cell activity to understand the effects of Venetoclax on T cells and develop novel strategies for treating AML. We will examine the levels of Bcl-2 family proteins in T cells of AML patients and the effect of inhibiting Bcl-2 family proteins on the ability of T cells to target AML. In culture and animal models, we will evaluate the efficacy of Bcl-2 family inhibitor drugs for treating AML alone or in combination with other cancer therapy. We anticipate that Bcl-2 family protein levels are increased in T cells of AML patients and associated with T cell dysfunction. We also expect that Bcl-2 family inhibitors will enhance the ability of T cells to target AML and work synergistically with other cancer therapy. Successful development of Bcl-2 family inhibitors as novel therapy for AML will provide a new approach for treating relapsed AML and increase the overall survival rate of AML patients.
Competitiondate
202410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Fang, Karen Kai-Lin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~